Dougan Brady W 4

What Happened

• Brady W. Dougan, a director of Humacyte, received a derivative equity award (reported as transaction type "A" — grant/award) on June 11, 2026. The Form 4 shows 0 shares acquired at $0.00 (no immediate cash value recorded).
• The award is subject to a vesting schedule: the first 25% becomes exercisable on June 11, 2027, then 1/48 of the award vests on the 11th of each month thereafter through June 11, 2030. This indicates multi-year vesting rather than an immediate purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely filing).
• Reported amount acquired: 0 shares; reported purchase price: $0.00 (derivative award).
• Vesting/footnote: First 25% vests on 6/11/2027; remaining vests monthly (1/48) through 6/11/2030 (four-year schedule).
• Shares owned after transaction: Not specified on the reported entry.
• Transaction code: A = Award/Grant (derivative). No exercise or sale was reported.

Context

• A derivative award on a Form 4 typically reflects an equity grant such as stock options or other awards that convert to shares only as they vest or are exercised; no shares or proceeds were realized at grant.
• Director awards are common as compensation and do not by themselves indicate a buy/sell view of the stock. The filing was timely, so there’s no late-reporting concern for investors.